Dr Julia Gee

Senior Lecturer

Ysgol Fferylliaeth a Gwyddorau Fferyllol

: Gee@caerdydd.ac.uk
: +44 29208 74922

: Ar gael fel goruchwyliwr ôl-raddedig

Ymunais ag Ysgol Fferylliaeth a Gwyddorau Fferyllol Caerdydd yn 2000 ac yn dilyn fy Nghymrodoriaeth Breast Cancer Now, cefais fy mhenodi’n Uwch Ddarlithydd yn yr Ysgol yn 2015. Mae fy ymchwil yng ngrŵp Ffarmacoleg Foleciwlaidd Canser y Fron yn canolbwyntio ar ddeall ymateb therapiwtig a methiant mewn canser y fron, yn enwedig mewn perthynas â thriniaethau gwrth-hormonaidd sy'n atal signalau derbynyddion estrogen a therapïau wedi'u targedu ymhellach. Mae fy ymchwil yn defnyddio modelau celloedd arbrofol unigryw yr ydym wedi'u datblygu yn yr Ysgol i ddynwared ymwrthedd, yn ogystal â samplau tiwmor cleifion.

Arweiniodd ein grŵp y cysyniad y gall triniaethau canser o'r fath ysgogi llwybrau signalau goroesiad cydadferol a goroesi celloedd mewn canser y fron sy'n cyfyngu ar eu gwerth therapiwtig ac yn ysgogi datblygiad ymwrthedd. Ar hyn o bryd mae gennyf ddiddordeb mewn archwilio colli derbynnydd estrogen a’r enillion mewn signalau amgen a all ddigwydd ar ôl triniaeth wrth-hormonau hirdymor. Mae nifer o fecanweithiau nad oeddent wedi'u cysylltu o'r blaen ag ymwrthedd gwrth-hormonau yn dod i'r amlwg o'r astudiaethau signalau. Mae'r gwaith hwn yn bwysig oherwydd bod ymwrthedd yn datblygu mewn o leiaf draean o gleifion canser y fron ac mae'n parhau i fod yn faes lle mae angen clinigol heb ei ddiwallu yn y clefyd hwn i raddau helaeth. Ein nod wrth ddehongli'r mecanweithiau hyn yw datgelu dulliau posibl o dargedu ymwrthedd gwrth-hormonau a'i ymddygiad ymosodol yn y dyfodol a hefyd darganfod biofarcwyr posibl ar gyfer canser y fron ag ymwrthedd.

Ochr yn ochr â'r astudiaethau triniaeth gwrth-hormonau hyn, mae gen i ddiddordeb hefyd mewn llwybrau therapiwtig mwy newydd a allai fod o werth yn y dyfodol mewn canser y fron - er enghraifft, rydym ar hyn o bryd yn gwerthuso sensitifrwydd therapi dynamig mewn gwahanol isdeipiau canser y fron gan ddefnyddio modelau celloedd. Gan ddefnyddio fy arbenigedd imiwnohistocemegol, rwyf hefyd wedi ymgymryd ag astudiaethau biofarcwyr trosiadol allweddol ar gyfer nifer o dreialon cenedlaethol o asiant newydd ar gyfer canser y fron mewn cydweithrediad â chydweithwyr clinigol. Yn flaenorol, mae'r rhain wedi cynnwys imiwnohistocemeg ar gyfer astudiaethau gyda'r gwrth-hormon Fulvestrant mewn canser y fron (ee treialon Astudiaeth 41 a NEWEST) ac yn fwyaf diweddar ar gyfer astudiaethau atalydd trosglwyddo signal wedi'u targedu newydd (ee treialon FURVA a STAKT), gyda rhai o'r astudiaethau hyn yn defnyddio samplau cleifion a gymerwyd yn olynol yn ystod ymateb triniaeth ac ailwaelu.

Rwy'n aelod o thema ymchwil yr Ysgol:

Darganfod Cyffuriau, y Gwyddorau Fferyllol a Therapiwteg Arbrofol (DDPSET)

Date
Type

2009

Robertson, J. F. R. et al. 2009. Tumor biomarker changes following pre-surgical treatment with 500 mg Fulvestrant plus Anastrozole Versus 500 mg Fulvestrant Alone and 1 mg Anastrozole Alone [Abstract]. Cancer Research 69(24S), pp. 491S. (10.1158/0008-5472.SABCS-09-24)
Morgan, L. D. et al. 2009. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biology and Therapy 8(16), pp. 1550-1558. (10.4161/cbt.8.16.8954)
Kuter, I., Anderson, E., Emeribe, U., Finlay, P., Nicholson, R. I. and Gee, J. M. W. 2009. Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST) [Abstract]. Journal of Clinical Oncology 27(15S), article number: e11602.
Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. 162 Altered Histone Modifications and their regulating enzymes in Fulvestrant resistant breast cancer cell line In Vitro [Abstract]. Laboratory Investigation 89(S1), pp. 38A-39A. (10.1038/labinvest.2008.132)
Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Taylor, K. M. and Gee, J. M. W. 2009. Experimental endocrine resistance: concepts and strategies. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 1-26., (10.1007/978-1-4020-8526-0_1)
Gee, J. M. W. et al. 2009. The dark side of antihormonal action in breast cancer. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential. Dordrecht: Springer, pp. 63-84., (10.1007/978-1-4020-8526-0_4)
Hiscox, S. E., Jordan, N. J., Morgan, L. D., Smith, C., Goddard, L., Gee, J. . M. W. and Nicholson, R. 2009. Adverse features of acquired antihormone resistance and their targeting. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. London: Springer, pp. 139-160., (10.1007/978-1-4020-8526-0_8)
Gee, J. M. W. et al. 2009. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. The Journal of Pathology 217(1), pp. 32-41. (10.1002/path.2430)
Hiscox, S. E., Jordan, N. J., Crandon-Lewis, A., Jiang, W., Nicholson, R. I. and Gee, J. M. W. 2009. Overexpression of L1CAM accompanies acquired endocrine resistance and is associated with the development of an aggressive cell phenotype [Abstract]. Cancer Research 69(2), pp. 213S-213S. (10.1158/0008-5472.SABCS-3028)
Shou, J., Osborne, K. C., Gee, J. M. W., Nicholson, R. I. and Schiff, R. 2009. Akt-dependent phosphorylation on AIB1 serine 967 contributes to breast cancer tamoxifen resistance [Abstract]. Cancer Research 69(2), pp. 211S-211S. (10.1158/0008-5472.SABCS-3021)
Elsheikh, S. E., Green, A. R., McClelland, R. A., Hutcheson, I. R., Gee, J. M. W., Nicholson, R. I. and Ellis, I. O. 2009. Altered Histone Modifications and Their Regulating Enzymes in Fulvestrant Resistant Breast Cancer Cell Line In Vitro [Abstract]. Modern Pathology 22(S1), pp. 38A-39A., article number: 162. (10.1038/modpathol.2008.210)
Jasani, B., Gee, J. M. W., Hutcheson, I. R., Clarkson, R. W. E., Bartlett, J. and Barrett-Lee, P. 2009. Resistance to HER2-directed trastuzumab therapy in breast cancer. Advances in Breast Cancer 6(3), pp. 11-18.
Kuter, I., Anderson, E., Emeribe, U., Finlay, P., Nicholson, R. I. and Gee, J. M. W. 2009. Comparison of Methods for Detection of Fulvestrant-Induced Changes in Breast Tumor Estrogen and Progesterone Receptor Expression in a Neoadjuvant Trial (NEWEST). Cancer Research 69(24), pp. 566S-567S.
O'Brien, C. S., Howell, S. J., Gee, J. M. W., Lykkesfeldt, A. E., Nicholson, R. I. and Clarke, R. B. 2009. Tamoxifen resistance in Estrogen Receptor Positive (ER plus ) breast cancer is driven by Estrogen Receptor Negative (ER-) cancer stem-like cells [Abstract]. Cancer Research 69(24), pp. 807S.

2008

Law, J. H. et al. 2008. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68(24), pp. 10238-10246. (10.1158/0008-5472.CAN-08-2755)
Davison, Z., Dutkowski, C. M., Gee, J. M. W., Nicholson, R. I. and Heard, C. M. 2008. In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin. Pharmaceutical Research 25(11), pp. 2516-2525. (10.1007/s11095-008-9665-5)
Knowlden, J. M., Jones, H. E., Barrow, D., Gee, J. M. W., Nicholson, R. I. and Hutcheson, I. R. 2008. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), pp. 79-91. (10.1007/s10549-007-9763-9)
Hiscox, S. E., Goddard, L., Jordan, N. J., Smith, C., Harper, M. E., Nicholson, R. I. and Gee, J. M. W. 2008. Overexpression of CD44 in acquired tamoxifen-resistant breast cancer cells augments their migratory response to heregulin beta 1 [Abstract]. Breast Cancer Research 10(S2), article number: P34. (10.1186/bcr1918)
Stone, A., Jones, H., Giles, M., Gee, J. M. W. and Nicholson, R. I. 2008. Anti-oestrogen therapy switches off tumour suppressors and proapoptotic genes in breast cancer and reveals a new therapeutic opportunity [Abstract]. Breast Cancer Research 10(s2), article number: P41. (10.1186/bcr1925)
Bensmail, A., Hutcheson, I. R., Giles, M., Gee, J. M. W. and Nicholson, R. I. 2008. Loss of oestrogen receptor alpha in long-term antioestrogen-resistant cells: reversal by a c-src inhibitor [Abstract]. Breast Cancer Research 10(S2), article number: O3. (10.1186/bcr1883)
Borley, A. C., Hiscox, S. E., Gee, J. M. W., Smith, C., Shaw, V., Barrett-Lee, P. and Nicholson, R. I. 2008. Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells. Breast Cancer Research 10(6), article number: R103. (10.1186/bcr2206)
Habashy, H. O. et al. 2008. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. European Journal of Cancer 44(11), pp. 1541-1551. (10.1016/j.ejca.2008.04.020)
Rakha, E. A. et al. 2008. Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. European Journal of Cancer 44(1), pp. 73-83. (10.1016/j.ejca.2007.10.009)
Taylor, K. M., Jordan, N. J., Hiscox, S. E., Gee, J. M. W. and Nicholson, R. I. 2008. Zinc transporter HKE4 as a new target in antihormone resistance of breast cancer [Abstract]. Breast Cancer Research 10(s2), article number: P42. (10.1186/bcr1926)
Thompson, A. et al. 2008. Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research 10(2), article number: R26. (10.1186/bcr1983)
Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Taylor, K. M., Hiscox, S. E. and Gee, J. M. W. 2008. Compensatory signalling induced by anti-hormone and anti-growth factor therapies in breast cancer: a starting point for the development of resistance to targeted therapies.. In: Pasqualini, J. R. ed. Breast cancer: prognosis, treatment and prevention. 2nd ed. London: Informa Healthcare, pp. 123-136.
Hutcheson, I. R., Gee, J. M. W. and Nicholson, R. I. 2008. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. and Thompson, A. M. eds. Prognostic and predictive factors in breast cancer. 2nd ed.. London: Informa Healthcare, pp. 122-138.

2007

Borley, A. C., Barrett-Lee, P., Gee, J. M. W., Show, V. E., Nicholson, R. and Hiscox, S. E. 2007. Anti-estrogens promote an invasive phenotype in intercellular adhesion deficient breast cancer cells. Breast Cancer Research and Treatment 106(Supp 1), pp. S7-S8.
Rampaul, R. S. et al. 2007. O-105 erbB Signalling in breast cancer. EJC Supplements 5(3), pp. 32. (10.1016/S1359-6349(07)71795-0)
Assender, J. W., Gee, J. M. W., Lewis, I., Ellis, I. O., Robertson, J. F. R. and Nicholson, R. I. 2007. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. Journal of Clinical Pathology 60(11), pp. 1216-1221. (10.1136/jcp.2006.041616)
Greco, F., Vicent, M. J., Gee, S., Jones, A. T., Gee, J. M. W., Nicholson, R. I. and Duncan, R. 2007. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-Dox-AGM in breast cancer cells. Journal of Controlled Release 117(1), pp. 28-39. (10.1016/j.jconrel.2006.10.012)
Hutcheson, I. R. et al. 2007. Heregulin beta 1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Research 9(4), article number: R50. (10.1186/bcr1754)
Nicholson, R. I., Hutcheson, I. R., Jones, H. E., Hiscox, S. E., Giles, M., Taylor, K. M. and Gee, J. M. W. 2007. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Reviews in Endocrine and Metabolic Disorders 8(3), pp. 241-253. (10.1007/s11154-007-9033-5)
Rakha, E. A. et al. 2007. Biologic and clinical characteristics of breast cancer with single hormone receptor-positive phenotype. Journal of Clinical Oncology 25(30), pp. 4772-4778. (10.1200/jco.2007.12.2747)
Rampaul, R. S. et al. 2007. Assessment of Her-2 status using a panel of antibodies and FISH. EJC Supplements 5(3), pp. 17.
Robertson, J. F. R. et al. 2007. Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer. European Journal of Cancer 43(1), pp. 64-70. (10.1016/j.ejca.2006.08.019)

2006

Hutcheson, I. R. et al. 2006. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine-Related Cancer 13(S1), pp. S89-S97. (10.1677/erc.1.01279)
Gee, J. M. W., Shaw, V. E., Hiscox, S. E., McClelland, R. A., Rushmere, N. K. and Nicholson, R. I. 2006. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications. Endocrine-Related Cancer 13(S1), pp. S77-S88. (10.1677/erc.1.01274)
Jones, H. E., Gee, J. M. W., Hutcheson, I. R., Knowlden, J. M., Barrow, D. and Nicholson, R. I. 2006. Growth factor receptor interplay and resistance in cancer. Endocrine-Related Cancer 13(S1), pp. S45-S51. (10.1677/erc.1.01275)
Nicholson, R. I., Gee, J. M. W., Harris, A. and Anderson, E. 2006. Consensus Statement. Endocrine-Related Cancer 13(S1), pp. S1-S2. (10.1677/erc.1.01323)
Burmi, R. S., McClelland, R. A., Barrow, D., Ellis, I. O., Robertson, J. F. R., Nicholson, R. I. and Gee, J. M. W. 2006. Microarray studies reveal novel genes associated with endocrine resistance in breast cancer [Abstract]. Breast Cancer Research 8(S2), article number: S11. (10.1186/bcr1554)
Sarwar, N. et al. 2006. Phosphorylation of ER alpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER alpha phosphorylation in breast cancer progression. Endocrine-Related Cancer 13(3), pp. 851-861. (10.1677/erc.1.01123)
Jones, H. E., Gee, J. M. W., Barrow, D., Tonge, D., Holloway, B. and Nicholson, R. I. 2006. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. British Journal of Cancer 95(2), pp. 172-180. (10.1038/sj.bjc.6603237)
Jones, H. E., Gee, J. M. W., Hutcheson, I. R. and Nicholson, R. I. 2006. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online 9(7), article number: e27. (10.1017/S1470903106005451)
Hiscox, S. E., Morgan, L. D., Green, T. P., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2006. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast cancer research and treatment 97(3), pp. 263-274. (10.1007/s10549-005-9120-9)
Britton, D. J. et al. 2006. Bidirectional cross talk between ER alpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Research and Treatment 96(2), pp. 131-146. (10.1007/s10549-005-9070-2)
Jasani, B., Douglas-Jones, A. G., Rhodes, A., Wozniak, S., Barrett-Lee, P., Gee, J. M. W. and Nicholson, R. I. 2006. Measurement of estrogen receptor status by immunocytochemistry in paraffin wax sections. In: Brooks, S. A. and Harris, A. eds. Breast Cancer Research Protocols. Methods in Molecular Medicine Vol. 120. Totowa, NJ: Humana Press, pp. 127-146., (10.1385/1-59259-969-9:127)
Jones, H. E., Gee, J. M. W., Barrow, D., Holloway, B., Tonge, D. and Nicholson, R. I. 2006. Maintenance of EGFR phosphorylation by the IGF-1R in the presence of gefitinib in lung cancer cells: Co-targeting the EGFR and IGF-1R maximises anti-tumour effects [Abstract]. Annals of Oncology 17(S3), pp. iii39. (10.1093/annonc/mdl919)
Ali, S. et al. 2006. Immunohistochemical determination of estrogen receptor-alpha phosphorylation in activation function AF1 in primary and tamoxifen-resistant breast cancer is indicative of a complex role for estrogen receptor-alpha phosphorylation in breast cancer progression [Abstract]. Breast Cancer Research and Treatment 100(S1), pp. S36-S37. (10.1007/s10549-006-5678-0)

2005

Knowlden, J. M., Hutcheson, I. R., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2005. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor. Endocrinology 146(11), pp. 4609-4618. (10.1210/en.2005-0247)
Nicholson, R. I., Hutcheson, I. R., Hiscox, S. E., Knowlden, J. M., Giles, M. G., Barrow, D. and Gee, J. M. W. 2005. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocrine-Related Cancer 12(S1), pp. S29-S36. (10.1677/erc.1.00991)
Gee, J. M. W. et al. 2005. Consensus statement. Endocrine-Related Cancer 12(S1), pp. S1-S7. (10.1677/erc.1.01054)
Jones, H. E., Gee, J. M. W., Taylor, K. M., Barrow, D., Williams, H. D., Rubini, M. and Nicholson, R. I. 2005. Development of strategies for the use of anti-growth factor treatments. Endocrine-Related Cancer 12(S1), pp. S173-S182. (10.1677/erc.1.01004)
Agrawal, A., Gutteridge, E., Gee, J. M. W., Nicholson, R. I. and Robertson, J. F. R. 2005. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocrine-Related Cancer 12(S1), pp. S135-S144. (10.1677/erc.1.01059)
Staka, C. M., Nicholson, R. I. and Gee, J. M. W. 2005. Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocrine-Related Cancer 12(S1), pp. S85-S97. (10.1677/erc.1.01006)
Gee, J. M. W., Robertson, J. F., Gutteridge, E., Ellis, I. O., Pinder, S. E., Rubini, M. and Nicholson, R. I. 2005. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocrine-Related Cancer 12(S1), pp. S99-S111. (10.1677/erc.1.01005)
Gutteridge, E., Gee, J. M. W., Nicholson, R. I. and Robertson, J. F. R. 2005. Biological markers associated with response to gefitinib ('Iressa') in patients with breast cancer [Abstract]. British Journal of Surgery 92(S1), pp. 13-17. (10.1002/bjs.5008)
Green, A. R., Paish, E. C., Gee, J. M. W., Nicholson, R. I., Cheung, K. L., Robertson, J. F. R. and Ellis, I. O. 2005. Oestrogen receptor variant expression as potential selectors for adjuvant endocrine therapy in breast cancer patients [Abstract]. Journal of Pathology 205(S1), pp. 5A. (10.1002/path.1762)
Nicholson, R. I. et al. 2005. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. The Journal of Steroid Biochemistry and Molecular Biology 93(2-5), pp. 257-262. (10.1016/j.jsbmb.2004.12.006)
Gee, J. M. W. and Hutcheson, I. R. 2005. Understanding endocrine resistance: the critical need for sequential samples from clinical breast cancer and novel in vitro models [Viewpoint]. Breast Cancer Research 7(5), pp. 187-189. (10.1186/bcr1289)
Giles, M. G., Fiegl, H., Widschwendter, M., Gee, J. M. W., Wakeling, A. E. and Nicholson, R. I. 2005. Loss of estrogen receptor (ER) expression in MCF-7 cells following long-term exposure to fulvestrant [Abstract]. Breast Cancer Research and Treatment 94(S1), pp. S243. (10.1007/s10549-005-1234-6)

2004

Nicholson, R. I., Staka, C., Boyns, F. E., Hutcheson, I. R. and Gee, J. M. W. 2004. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy. Endocrine-Related Cancer 11(4), pp. 623-641. (10.1677/erc.1.00778)
Jones, H. E. et al. 2004. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-Related Cancer 11(4), pp. 793-814. (10.1677/erc.1.00799)
Jordan, N. J., Gee, J. M. W., Barrow, D., Wakeling, A. E. and Nicholson, R. I. 2004. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Research and Treatment 87(2), pp. 167-180. (10.1023/B:BREA.0000041623.21338.47)
Gutteridge, E., Gee, J. M. W., Nicholson, R. I. and Robertson, J. F. R. 2004. Biological markers associated with response to gefitinib (ZD1839) in patients with breast cancer [Abstract]. Journal of Clinical Oncology 22(14S), article number: 648.
Rushmere, N. K., Knowlden, J. M., Gee, J. M. W., Harper, M. E., Robertson, J. F. R., Morgan, B. P. and Nicholson, R. I. 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. International Journal of Cancer 108(6), pp. 930-936. (10.1002/ijc.11606)
Hutcheson, I. R., Gee, J. M. W., Barrow, D., Jones, H. E., Wakeling, A. E. and Nicholson, R. I. 2004. Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib ('Iressa') or trastuzumab (Herceptin((R))) generates cross-resistant phenotypes [Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S145-S146. (10.1007/s10549-004-3602-z)
Nicholson, R. et al. 2004. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10(1), pp. 346s-354s. (10.1158/1078-0432.CCR-031206)
Gee, J. M. W., Gutteridge, E., Robertson, J. F., Wakeling, A. E., Jones, H. E. and Nicholson, R. I. 2004. Biological markers during early treatment of tamoxifen resistant breast cancer with gefitinib ('Iressa')[Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S32. (10.1007/s10549-004-3602-z)
Gee, J. M. W., Giles, M. G. and Nicholson, R. I. 2004. Extreme growth factor signalling can promote oestrogen receptor-alpha loss: therapeutic implications in breast cancer. Breast Cancer Research 6(4), pp. 162-163. (10.1186/bcr904)
Giles, M. G., Gee, J. M. W., Wakeling, A. E. and Nicholson, R. I. 2004. Characterization of ER alpha and cofactor recruitment during fulvestrant treatment and resistance in breast cancer using chromatin immunoprecipitation [Abstract]. Breast Cancer Research and Treatment 88(S1), pp. S216-S217. (10.1007/s10549-004-3602-z)
Nicholson, R. et al. 2004. Chapter 16: beyond antihormones in the targeted therapy of breast cancer. In: Ingle, J. N. and Dowsett, M. eds. Endocrine Therapy for Breast Cancer Proceedings of the 2003 Gleneagles Conference. New York: Marcel Dekker, pp. 249-258.

2003

Gee, J. M. W., Harper, M., Hurcheson, I. and Madden, T. 2003. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144(11), pp. 5105-5117. (10.1210/en.2003-0705)
Hutcheson, I. R., Knowlden, J. M., Madden, T., Barrow, D., Gee, J. M. W., Wakeling, A. E. and Nicholson, R. I. 2003. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Research and Treatment 81(1), pp. 81-93. (10.1023/A:1025484908380)
Knowlden, J. M. et al. 2003. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), pp. 1032-1044. (10.1210/en.2002-220620)
Britton, D. J., Hutcheson, I. R., Barrow, D., McClelland, R. A., Gee, J. M. W. and Nicholson, R. I. 2003. Oestrogen receptor phosphorylation in hormone sensitive and anti-hormone resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S61. (10.1023/A:1026252325164)
Nicholson, R. I., Gee, J. M. W., Knowlden, J. M., McClelland, R. A., Madden, T., Barrow, D. and Hutcheson, I. R. 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80(S1), pp. 29-34. (10.1023/A:1025467500433)
Nicholson, R. I. et al. 2003. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib ('Iressa', ZD1839) in MCF-7 human breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S171. (10.1023/A:1026252325164)
Hutcheson, I. R., Knowlden, J. M., Barrow, D., Gee, J. M. W., Robertson, J. F., Wakeling, A. E. and Nicholson, R. I. 2003. Heregulin-induced AKT activation promotes growth of gefitinib ('Iressa', ZD1839)-treated, tamoxifen-resistant breast cancer cells [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S170. (10.1023/A:1026252325164)
Gee, J. M. W., Rubini, M., Robertson, J. F., Ellis, I. O., Gutteridge, E. and Nicholson, R. I. 2003. Type 1 insulin-like growth factor receptor expression and activation in clinical breast cancer [Abstract]. Breast Cancer Research and Treatment 82(S1), pp. S102., article number: 429. (10.1023/A:1026252325164)
Gee, J. M. W. and Nicholson, R. I. 2003. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization [Commentary]. Breast Cancer Research 5(3), pp. 126-129. (10.1186/bcr584)
Gee, J. M. W. and Knowlden, J. M. 2003. ADAM metalloproteases and EGFR signalling [Viewpoint]. Breast Cancer Research 5(5), pp. 223-224. (10.1186/bcr637)
Hutcheson, I. R., Gee, J. M. W. and Nicholson, R. I. 2003. MAP Kinase family members and endocrine response and survival in breast cancer. In: Walker, R. A. ed. Prognostic and Predictive Factors in Breast Cancer. London: Martin Dunitz, pp. 147-166.

2002

Gee, J. M. W. et al. 2002. ZD1839 ('Iressa') improves the antitumour activity of tamoxifen ('Nolvadex') and ICI 182, 780 ('Faslodex') in antihormone responsive breast cancer [Abstract]. European Journal of Cancer 38(S7), pp. S59. (10.1016/S0959-8049(02)80835-8)
Nicholson, R. I., Hutcheson, I. R. and Gee, J. M. W. 2002. Targeting of oestrogen and growth factor signalling pathways in the therapy of breast cancer: Implications for chemoprevention [Abstract]. European Journal of Cancer 38(S3), pp. S43-S44. (10.1016/S0959-8049(02)81245-X)
Nicholson, R. I. et al. 2002. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. In: Castagnetta, L. et al. eds. Hormone-Related Tumors: Novel Approaches to Prevention and Treatment. Annals of the New York Academy of Sciences Vol. 963. New York: The New York Academy of Sciences, pp. 104-115., (10.1111/j.1749-6632.2002.tb04101.x)
Albanell, J. et al. 2002. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Journal of Clinical Oncology 20(1), pp. 110-124. (10.1200/JCO.20.1.110)
Chan, K. C., Knox, W. F., Gee, J. M. W., Morris, J., Nicholson, R. I., Potten, C. S. and Bundred, N. J. 2002. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Research 62, pp. 122-128.

2001

Wakeling, A. E., Nicholson, R. I. and Gee, J. M. W. 2001. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clinical Cancer Research 7(12), pp. 4350S-4355S.
Nicholson, R. I. et al. 2001. ZD1839 (Iressa) improves the antitumor activity of tamoxifen (Nolvadex) in antihormone-responsive breast cancer cells [Abstract]. Clinical Cancer Research 7(S), pp. 3766S.
Glynne-Jones, E. M. et al. 2001. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. International Journal of Cancer 94(2), pp. 178-184. (10.1002/ijc.1450)
Nicholson, R. I., Gee, J. M. W. and Harper, M. E. 2001. EGFR and cancer prognosis. European Journal of Cancer 37(S4), pp. 9-15. (10.1016/S0959-8049(01)00231-3)
Nicholson, R. I. et al. 2001. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-Related Cancer 8(3), pp. 175-182. (10.1677/erc.0.0080175)
Robertson, J. F. et al. 2001. Comparison of the short-term biological effects of 7 alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17 beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Research 61(18), pp. 6739-6746.
McClelland, R. A. et al. 2001. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142(7), pp. 2776-2788. (10.1210/en.142.7.2776)
Gee, J. M. W., Ellis, I., Nicholson, R. and Robertson, J. 2001. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. International Journal of Cancer 95(4), pp. 247-54. (10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S)
Kenny, F. S. et al. 2001. Effect of dietary GLA plus /-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts. International Journal of Cancer 92(3), pp. 342-347. (10.1002/ijc.1213)
Kenny, F. S., Willsher, P. C., Gee, J. M. W., Nicholson, R. I., Pinder, S. E., Ellis, I. O. and Robertson, J. F. R. 2001. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. Breast Cancer Research and Treatment 65(2), pp. 135-144. (10.1023/A:1006469627067)

2000

Yip, S. S. et al. 2000. Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. International Journal of Cancer 88(3), pp. 363-368. (10.1002/1097-0215(20001101)88:3<363::AID-IJC7>3.0.CO;2-4)
Madden, T., Barrow, D., McClelland, R. A., Gee, J. M. W. and Nicholson, R. I. 2000. Modulation of oestrogen action by receptor gene inhibition. European Journal of Cancer 36(S4), pp. 34-35. (10.1016/S0959-8049(00)00216-1)
Kenny, F. S., Pinder, S. E., Ellis, I. O., Gee, J. M. W., Nicholson, R. I., Bryce, R. P. and Robertson, J. F. R. 2000. Gamma linolenic acid with tamoxifen as primary therapy tn breast cancer. International Journal of Cancer 85(5), pp. 643-648. (10.1002/(SICI)1097-0215(20000301)85:5<643::AID-IJC8>3.0.CO;2-Z)
Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Ellis, I. O. and Nicholson, R. I. 2000. A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. International Journal of Cancer 89(2), pp. 209-212. (10.1002/(SICI)1097-0215(20000320)89:2<209::AID-IJC17>3.0.CO;2-6)
Gee, J. M. W., Barroso, A. F., Ellis, I. O., Robertson, J. F. R. and Nicholson, R. I. 2000. Biological and clinical associations of c-jun activation in human breast cancer. International Journal of Cancer 89(2), pp. 177-186. (10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0)
Nicholson, R. I. and Gee, J. M. W. 2000. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. British Journal of Cancer 82(3), pp. 501-513. (10.1054/bjoc.1999.0954)
Gee, J. M. W., Robertson, J. F. R., Ellis, I. O. and Nicholson, R. I. 2000. Abstract P13: Impact of activation of MAP kinase family members on endocrine response and survival in clinical breast cancer [Abstract]. European Journal of Cancer 36(S4), pp. 105. (10.1016/S0959-8049(00)00259-8)

1999

Gee, J. M. W., Robertson, J. F. R., Ellis, I. O., Nicholson, R. I. and Hurst, H. C. 1999. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. Journal of Pathology 189(4), pp. 514-520. (10.1002/(SICI)1096-9896(199912)189:4<514::AID-PATH463>3.0.CO;2-9)
Seery, L. T., Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Kenny, F. S., Ellis, I. O. and Nicholson, R. I. 1999. [Corrigendum] BRCA1 expression levels predict distant metastasis of sporadic breast cancer (vol 84, pg 258, 1999). International Journal of Cancer 84(5), pp. 544-544. (10.1002/(SICI)1097-0215(19991022)84:5<544::AID-IJC18>3.0.CO;2-9)
Nicholson, R. I., McClelland, R. A., Robertson, J. F. R. and Gee, J. M. W. 1999. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocrine-Related Cancer 6(3), pp. 373-387. (10.1677/erc.0.0060373)
Kenny, F. S. et al. 1999. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clinical Cancer Research 5(8), pp. 2069-2076.
McClelland, R. A., Gee, J. M. W., O'Sullivan, L. A., Barnes, D. M., Robertson, J. F. R., Ellis, I. O. and Nicholson, R. I. 1999. p21(WAF1) expression and endocrine response in breast cancer. Journal of Pathology 188(2), pp. 126-132. (10.1002/(SICI)1096-9896(199906)188:2<126::AID-PATH340>3.0.CO;2-O)
Seery, L. T., Knowlden, J. M., Gee, J. M. W., Robertson, J. F. R., Kenny, F. S., Ellis, I. O. and Nicholson, R. I. 1999. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. International Journal of Cancer 84(3), pp. 258-262. (10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H)
Davies, E. L., Gee, J. M. W., Cochrane, R. A., Jiang, W. G., Sharma, A. K., Nicholson, R. I. and Mansel, R. E. 1999. The immunohistochemical expression of desmoplakin and its role in vivo in the progression and metastasis of breast cancer. European Journal of Cancer 35(6), pp. 902-907. (10.1016/S0959-8049(99)00031-3)
Gee, J. M. W., Willsher, P. C., Kenny, F. S., Robertson, J. F. R., Pinder, S. E., Ellis, I. O. and Nicholson, R. I. 1999. Endocrine response and resistance in breast cancer: A role for the transcription factor Fos. International Journal of Cancer 84(1), pp. 54-61. (10.1002/(SICI)1097-0215(19990219)84:1<54::AID-IJC11>3.0.CO;2-X)

1998

Knowlden, J. M. et al. 1998. C-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17(15), pp. 1949-1957.
Kenny, F. S., Willsher, P. C., Gee, J. M. W., Nicholson, R. I., Ellis, I. O. and Robertson, J. F. R. 1998. Change in expression of ER and BCL-2 predict for quality and duration of response in endocrine sensitive breast cancer [Abstract]. European Journal of Cancer 34(S5), pp. S82. (10.1016/S0959-8049(98)80345-6)
Willsher, P. C. et al. 1998. c-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Research 18(5B), pp. 3695-3698.
Davies, E. L., Gee, J. M. W., Cochrane, R. A., Nicholson, R. I., Sharma, A. K., Jiang, W. G. and Mansel, R. E. 1998. The expression of desmoglein-2 in primary breast cancer and its relation to a series of prognostic markers [Abstract]. British Journal of Cancer 78(2), pp. 149. (10.1038/bjc.1998.457)
McClelland, R. A. et al. 1998. Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy. British Journal of Cancer 77(10), pp. 1653-1656. (10.1038/bjc.1998.457)

1997

Knowlden, J. M. et al. 1997. Use of reverse transcription-polymerase chain reaction methodology to detect estrogen-regulated gene expression in small breast cancer specimens. Clinical Cancer Research 3(11), pp. 2165-2172.
Dewhurst, L. O., Gee, J. M. W., Rennie, I. G. and MacNeil, S. 1997. Tamoxifen, 17 beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. British Journal of Cancer 75(6), pp. 860-868. (10.1038/bjc.1997.153)
Jones, H. E., Eaton, C. L., Barrow, D., Dutkowski, C. M., Gee, J. M. W. and Griffiths, K. 1997. Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30(4), pp. 219-231. (10.1002/(SICI)1097-0045(19970301)30:4<219::AID-PROS1>3.0.CO;2-G)
Nicholson, R. I., Gee, J. M. W., Harper, M. E., Ellis, I. O., Willsher, P. and Robertson, J. F. R. 1997. erbB signalling in clinical breast cancer: relationship to endocrine sensitivity. Endocrine-Related Cancer 4(3), pp. 297-305. (10.1677/erc.0.0040297)

1996

Sharma, A. K. et al. 1996. Analysis of the genes for oestrogen and epidermal growth factor receptors in human breast cancer. The Breast 5(5), pp. 344-350. (10.1016/S0960-9776(96)90002-8)
Sharma, A. K., Grimshaw, D., Horgan, K., Mansel, R. E., Gee, J. M. W. and Nicholson, R. I. 1996. Mechanisms responsible for oestrogen receptor expression in primary human breast cancer. The Breast 5(4), pp. 237-243. (10.1016/S0960-9776(96)90017-X)
Nicholson, R. I., Francis, A. B., Kyme, S. R. and Gee, J. M. W. 1996. Properties and mode of action of pure antioestrogens in breast cancer in vitro. The Breast 5(3), pp. 175-180. (10.1016/S0960-9776(96)90089-2)
McClelland, R. A., Gee, J. M. W., Francis, A. B., Robertson, J. F. R., Blamey, R. W., Wakeling, A. E. and Nicholson, R. I. 1996. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. European Journal of Cancer 32(3), pp. 413-416. (10.1016/0959-8049(95)00517-X)
Nicholson, R. I. et al. 1996. Pure antiestrogens - The most important advance in the endocrine therapy of breast cancer since 1896?. In: Castagnetta, L., Nenci, I. and Bradlow, H. L. eds. Basis for Cancer Management. Annals of the New York Academy of Sciences Vol. 784. New York: New York Academy of Sciences, pp. 325-335., (10.1111/j.1749-6632.1996.tb16247.x)
McClelland, R. A. et al. 1996. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Research and Treatment 41(1), pp. 31-41. (10.1007/BF01807034)
Gupta, S. K., Pace, D., Gee, J. M. W., Douglas-Jones, A. G., Morgan, J. M. and Mansel, R. E. 1996. Epithelial markers in lobular carcinoma [Abstract]. Journal of Pathology 179(S1), pp. 16A. (10.1002/path.1996.1711790502)

1995

Gee, J. M. W., Douglas-Jones, A. G., Hepburn, P., Sharma, A. K., McClelland, R. A., Ellis, I. O. and Nicholson, R. I. 1995. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. Journal of Pathology 177(3), pp. 285-293. (10.1002/path.1711770311)
Nicholson, R. I., McClelland, R. A. and Gee, J. M. W. 1995. Steroid hormone receptors and their clinical significance in cancer. Journal of Clinical Pathology 48(10), pp. 890-895. (10.1136/jcp.48.10.890)
Gee, J. M. W. et al. 1995. Immunocytochemical localization of fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer 64(4), pp. 269-273. (10.1002/ijc.2910640410)
Robertson, J. F. R., Gee, J. M. W., McClelland, R. A., Ellis, I. O., Willsher, P., Blamey, R. W. and Nicholson, R. I. 1995. BCL2 Expression In Breast-Cancer - Identification Of Patients Who Should Not Receive Endocrine Therapy [Abstract]. British Journal of Surgery 82(5), pp. 698. (10.1002/bjs.1800820540)
Hepburn, P. J., Glynne-Jones, E., Goddard, L., Gee, J. M. W. and Harper, M. E. 1995. Cell proliferation in prostatic carcinoma: comparative analysis of Ki-67, MIB-1 and PCNA. Histochemical Journal 27(3), pp. 196-203. (10.1007/BF00177586)
Manning, D. L. et al. 1995. Differential expression of estrogen-regulated genes in breast-cancer. Acta Oncologica 34(5), pp. 641-646.
Nicholson, R. I., Gee, J. M. W., Francis, A. B., Manning, D. L., Wakeling, A. E. and Katzenellenbogen, B. S. 1995. Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. Endocrine-Related Cancer 2(1), pp. 115-121. (10.1677/erc.0.0020115)
Nicholson, R. I., Gee, J. M. W., Manning, D. L., Wakeling, A. E., Montano, M. M. and Katzenellenbogen, B. S. 1995. Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen-Sensitive and-Resistant Experimental and Clinical Breast Cancer. In: Philibert, D. et al. eds. Steroid Receptors and Antihormones. Annals of the New York Academy of Sciences Vol. 761. New York: New York Academy of Sciences, pp. 148-163., (10.1111/j.1749-6632.1995.tb31376.x)

1994

Gee, J. M. W. et al. 1994. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer 59(5), pp. 619-628. (10.1002/ijc.2910590508)
Nicholson, R. I. et al. 1994. Transforming growth factor-α and endocrine sensitivity in breast cancer. Cancer Research 54(7), pp. 1684-1689.
Nicholson, R. I. et al. 1994. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Research and Treatment 29(1), pp. 117-125. (10.1007/BF00666187)
Manning, D. L. et al. 1994. Oestrogen-regulated genes in breast cancer: Association of pLIV1 with lymph node involvement. European Journal of Cancer 30(5), pp. 675-678. (10.1016/0959-8049(94)90543-6)
Nicholson, R. I., Francis, A. B., McClelland, R. A., Manning, D. L. and Gee, J. M. W. 1994. Pure anti-oestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete oestrogen withdrawal worthwhile?. Endocrine-Related Cancer 1(4), pp. 5-17. (10.1677/erc.0.0010005)
Ghandour, F. A., Attanoos, R. L., Nahar, K., Gee, J. M. W., Bigrigg, A. and Ismail, S. M. 1994. Immunocytochemical localization of oestrogen and progesterone receptors in primary adenocarcinoma of the cervix. Histopathology 24(1), pp. 49-55. (10.1111/j.1365-2559.1994.tb01270.x)
Nicholson, R. I. et al. 1994. Pure antioestrogens in breast cancer - experimental and clinical observations. Presented at: Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects: International Symposium, Milano, Italy, 10-14 April 1994 Presented at Motta, M. and Serio, M. eds.Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects: Proceedings of an International Symposium, Milano, Italy, 10-14 April 1994. International Congress Series Vol. 1064. Amsterdam: Elsevier Science pp. 347-360.

1993

Schmid, K. W. et al. 1993. Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchovs Archiv 422(2), pp. 153-159. (10.1007/BF01607167)
Manning, D. L., McClelland, R. A., Gee, J. M. W., Chan, C. M. W., Green, C. D., Blamey, R. M. and Nicholson, R. I. 1993. The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancer. European Journal of Cancer 29(10), pp. 1462-1468. (10.1016/0959-8049(93)90021-7)

1992

Jasani, B., Thomas, N. D., Navabi, H., Millar, D. M., Newman, G. R., Gee, J. M. W. and Williams, E. D. 1992. Dinitrophenyl (DNP) hapten sandwich staining (DHSS) procedure: A 10 year review of its principle reagents and applications. Journal of Immunological Methods 150(1-2), pp. 193-198. (10.1016/0022-1759(92)90078-8)

1991

Gee, J. M. W., Amselgruber, W. M., Jasani, B. and Nicholson, R. I. 1991. Use of the dinitrophenyl hapten sandwich staining procedure (DHSS) to localize estrogen receptors in paraffin-embedded tissues. Journal of Histochemistry & Cytochemistry 39(12), pp. 1659-1670. (10.1177/39.12.1719072)

1990

Nicholson, R. I., Walker, K. J., Bouzubar, N., Wills, R. J., Gee, J. M. W., Rushmere, N. K. and Davies, P. 1990. Estrogen Deprivation in Breast Cancer: Clinical, Experimental, and Biological Aspects. In: Castagnetta, L. et al. eds. Steroid Formation, Degradation, and Action in Peripheral Tissues. Annals of the New York Academy of Sciences Vol. 595. New York: New York Academy of Sciences, pp. 316-327., (10.1111/j.1749-6632.1990.tb34305.x)
Gee, J. M. W., Nicholson, R. I., Jasani, B., Newman, G. R. and Amselgruber, W. M. 1990. An immunocytochemical method for localization of estrogen receptors in rat tissues using a dinitrophenyl (DNP)-labeled rat monoclonal primary antibody. Journal of Histochemistry & Cytochemistry 38(1), pp. 69-78. (10.1177/38.1.1688451)

1988

Nicholson, R. I., Gotting, K. E., Gee, J. M. W. and Walker, K. J. 1988. Actions of oestrogens and antioestrogens on rat mammary gland development: Relevance to breast cancer prevention. Journal of Steroid Biochemistry 30(1-6), pp. 95-103. (10.1016/0022-4731(88)90081-7)

Meysydd ymchwil:

Arwyddion gwrth-hormonau a cholled ER mewn canser y fron ER+.
Mecanweithiau twf a chynnydd canser y fron sy’n ymwrthol i ffactorau gwrth-hormon a gwrth-dwf
Darganfod targed newydd a gwerthusiad cyn-glinigol o therapïau newydd gan ddefnyddio modelau canser y fron.
Astudiaethau trawsgludo signal trosiadol a biofarcwr mewn canserau clinigol y fron

Arbenigedd ymchwil:

Canser y fron a bioleg ymwrthedd gwrth-hormonau clinigol ac arbrofol
Derbynnydd steroid a derbynnydd ffactor twf/trawsgludiad signal cinas;
Biofarciwr newydd a darganfyddiad targed
Imiwnocytocemeg glinigol ac arbrofol, gan gynnwys defnyddio gwrthgyrff ffosffo-benodol.
Modelau celloedd sy'n gwrthsefyll triniaeth
Micro-araeau genynnau a biowybodeg cysylltiedig.

Mae fy niddordebau ymchwil wedi'u cyfeirio'n bennaf at gael gwerthfawrogiad llawnach o fioleg canser y fron, mecanweithiau methiant cyfryngau gwrth-hormonaidd a'r cynnydd cysylltiedig o brognosis gwaeth.

Yn fy PhD, defnyddiais ficrosgopeg electronau ac imiwnocytocemeg i archwilio effaith gwrth-hormonau ar y fron arferol. Roedd yr efrydiaeth yn cynnwys optimeiddio gweithdrefnau imiwnocytocemegol newydd i fonitro derbynnydd estrogen (ER) mewn canser y fron clinigol ac arbrofol, protein sydd bellach yn cael ei fesur yn rheolaidd yn y clinig. Roedd fy swyddi ôl-ddoethurol dilynol yn canolbwyntio ar fonitro derbynnydd estrogen a dadreoleiddio trawsgludo signal pellach mewn DCIS clinigol, ac yna yn fy swydd fel Uwch Gydymaith Ymchwil ar gyfer Canolfan Tenovus ar gyfer Ymchwil Canser yn archwilio canser ymledol y fron, gan bennu trawsnewid signal twf ffactor sy'n sail i ymwrthedd i wrth-hormonau a ffactorau gwrth-dwf mewn modelau arbrofol a chlefydau clinigol. Nod yr astudiaethau olaf hyn oedd nid yn unig datgelu biomarcwyr o fethiant cyffuriau newydd, ond hefyd dargedau therapiwtig newydd.

Yn dilyn hynny dechreuais ymddiddori mewn dehongli a thargedu'r signalau oncogenig a achosir yn baradocsaidd gan wrth-hormonau yn ystod y cyfnod ymatebol i gyffuriau o ganser y fron ER+ sy'n cyfyngu ar yr ymateb twf-atal twf cychwynnol mwyaf posibl ac yn cynorthwyo ymddangosiad ymwrthedd. Deilliodd y maes ymchwil newydd hwn, a arloeswyd gan ein grŵp Ffarmacoleg Foleciwlaidd Canser y Fron yn Ysgol Fferylliaeth a Gwyddorau Fferyllol Caerdydd, o’n hastudiaethau sy’n dangos sefydlu cydadferol o signalau erbB gan wrth-hormonau. Roedd canfyddiadau in vitro’r grŵp gan ddefnyddio modelau canser y fron yn dangos bod potensial i dargedu signalau cydadferol, gyda’n hastudiaethau nodedig yn dangos gwerth cyd-dargedu EGFR, HER2 neu Src a achosir ar y cyd ochr yn ochr ag asiantau gwrth-hormonaidd mewn canser y fron ER+. Roedd y gwaith hwn yn cynnwys llawer o gydweithio â Diwydiant ar eu rhaglenni datblygu cyffuriau canser mewn celloedd canser y fron ag ymwrthedd. Yn dilyn hynny fe wnaeth fy Nghymrodoriaeth Wyddonol Breast Cancer Now ganiatáu i mi ystyried gallu amlygiad gwrth-hormonaidd estynedig i ail-raglennu canser y fron ER+ yn radical, gan gwmpasu astudiaethau canser y fron in vitro a chlinigol a datgelu y gallai colled ER ddigwydd hefyd o ganlyniad uniongyrchol i ganser y fron o'r fath driniaeth. Fe wnaeth y Gymrodoriaeth ddyfnhau fy ngwybodaeth ymwrthedd, gwella fy sgiliau biowybodeg, a chaniatáu i mi ffynnu ymhellach fel ymchwilydd annibynnol mewn canser y fron, gan arwain at fy mhenodiad fel Uwch Ddarlithydd yn yr Ysgol. Roedd hefyd yn caniatáu datblygu panel mawr o fodelau celloedd gwrth-hormon hirdymor o ffenoteipiau ER+ lluosog sy'n adnodd pwysig yn ein hymchwil barhaus ac ar gyfer ein hastudiaethau cydweithredol.

Diddordebau ymchwil cyfredol:

1. Darganfod mecanweithiau ymwrthedd sy'n ganlyniad i driniaeth gwrth-hormon hirdymor

Mae astudiaethau o wrthwynebiad gwrth-hormon a gaffaelwyd gyda chanser y fron yn aml yn defnyddio modelau in vitro gwrth-hormon cymharol fyrdymor (~ 12 mis) wedi'u trin â hormonau, gan awgrymu derbynyddion erbB, kinasau i lawr yr afon ac ER crosstalk. Fodd bynnag, mae targedu signalau ymgeiswyr o'r fath yn gyffredinol wedi bod yn siomedig yn glinigol ac mae gan asiantau endocrin ail linell fanteision cyfyngedig. Mae astudiaethau ein grŵp yn nodi y gall celloedd canser y fron sy'n gwrthsefyll hormonau yn y tymor hwy (~ 3 blynedd) recriwtio llwybrau twf / goresgyniad amgen newydd, ennill signalau sy'n lleihau / yn distewi ER, ac sy'n ymosodol iawn, gyda llai o effeithlonrwydd asiant ail linell. Felly gallai'r amlygiad gwrth-hormon cynorthwyol hirfaith cyn ailwaelu clinigol fod yn hollbwysig wrth hyrwyddo'r mecanwaith ymwrthedd a'r ffenoteip. Ymhlith y llwybrau newydd yr ydym yn eu cynnwys yn ein hymchwil mae signalau llwybr HIPPO, kinase signalau amgen sydd hefyd yn cynyddu mewn samplau canser y fron clinigol ag ymwrthedd, a moleciwlau tebyg i tetraspanin. Mae'r mecanweithiau hyn yn cael eu harchwilio ar hyn o bryd yn ein modelau celloedd gwrth-hormon hirdymor (gan gynnwys trwy broffilio micro-arae a biowybodeg) ac mewn samplau clinigol. Drwy ddehongli mecanweithiau o'r fath, y nod yw darganfod targedau therapiwtig newydd a allai fod yn well yn y pen draw i oedi neu drin ail bwl o ganser y fron clinigol. Er enghraifft, rydym wedi nodi rhai cyfuniadau cyffuriau sydd yn ôl pob golwg yn gallu adennill derbynyddion estrogen yn rhannol ac felly sensitifrwydd triniaeth gwrth-hormon yn ein modelau celloedd gwrthsefyll hirdymor gyda cholled ER, canfyddiadau a allai fod â pherthnasedd clinigol yn y pen draw gan fod tua 15% o ganserau’r fron hefyd yn colli’r derbynnydd hwn yn yr ail bwl.

2. Ymchwilio i therapïau newydd a manteisio arnynt, gan gynnwys mewn canserau clinigol y fron

Mae gan ein grŵp hanes hir o gydweithio â Diwydiant a chlinigwyr i archwilio cyffuriau newydd, yn ein modelau celloedd a thrwy ein hymwneud ag astudiaethau biofarciwr mewn treialon clinigol canser y fron. Mae ein hymchwil model gwrth-hormon wedi nodi bod cydrannau signalau RET, gan gynnwys ei gyd-dderbynyddion GFR-alffa, yn cael eu dadreoleiddio mewn gwrthiant. Mae celloedd o'r fath yn dibynnu ar y signalau hyn ac felly gellir eu targedu'n effeithiol iawn yn y labordy gan ddefnyddio atalyddion RET, tra bod kinase pellach sy'n gysylltiedig yn aml â gwrthiant yn AKT y gellir ei atal yn llwyddiannus hefyd i reoli twf celloedd gwrthsefyll. Yn ddiweddar mae ein hastudiaeth o driniaethau canser newydd wedi adeiladu ymhellach ar ganfyddiadau addawol hyn y system enghreifftiol - rydym wedi cynnal astudiaethau trosiadol (imiwnohistocemegol) mewn samplau canser y fron o dreialon clinigol STAKT (atalydd AKT) ac FURVA (atalydd RET) sy'n archwilio trawsgludiad signal o'r fath atalyddion.

Mae fy myfyriwr PhD hefyd yn gwerthuso sensitifrwydd therapi ffotodeinamig (PDT) mewn panel o fodelau celloedd sy'n adlewyrchu gwahanol isdeipiau canser y fron ac ochr yn ochr â thriniaethau confensiynol, er mwyn dehongli ymateb PDT a mecanweithiau ymwrthedd. Dylai'r ymchwil hwn nodi sut i wneud y mwyaf o effaith y dull therapiwtig newydd posibl pellach hwn.

Cydweithwyr ymchwil cenedlaethol a rhyngwladol cyfredol:

Mae gennyf gydweithrediadau yn yr Ysgol Fferylliaeth a Gwyddorau Fferyllol Caerdydd gyda S Hiscox, K Taylor, E Kidd, a hefyd P Prokopovich a C Simons
J Robertson (Athro Llawfeddygaeth, Ysbyty Brenhinol Derby), Prifysgol Nottingham
A Green (Grŵp Ymchwil Patholeg y Fron, Ysgol Feddygaeth), Sefydliad Bioddarganfod Prifysgol Nottingham
R Clarkson (Ysgol y Biowyddorau, Prifysgol Caerdydd)
M Y Fflint, Ysgol Fferylliaeth a Gwyddorau Biomoleciwlaidd, Prifysgol Brighton
R Clarke a B Simoes, Grŵp Bioleg y Fron, Canolfan y Fron Manceinion, Prifysgol Manceinion
C Ormandy, Bioleg Canser, Sefydliad Ymchwil Feddygol Garvan, Awstralia
S Clark, Labordy Ymchwil Epigenetics, Sefydliad Ymchwil Feddygol Garvan, Awstralia
M Milevskiy, Sefydliad Ymchwil Feddygol Walter ac Eliza Hall, Awstralia

Cyrff cyllido a diwydiant sydd wedi cefnogi ein hymchwil:

Canser y Fron Nawr
Prifysgol Nottingham
AstraZeneca
Cronfeydd Elusennol Ymddiriedolaeth GIG Felindre

MPharm:

PH1124 Systemau Corff Dynol: darlithydd ar gyfer endocrinoleg atgenhedlu
PH3101 Optimeiddio Dylunio Cyffuriau: darlithydd ar gyfer asiantau gwrth-hormonaidd mewn canser y fron
PH4116 Prosiect Ymchwil Fferylliaeth: goruchwyliwr prosiect ymchwil (ymchwil yn y labordy a fel arall) ac aelod o dîm modiwl PH4116
Cyfrannu at farcio OSCE ar gyfer MPharm blynyddoedd 1-4

MSc Bioleg Canser a Therapiwteg:

Fel Uwch Ddarlithydd craidd ar gyfer y rhaglen MSc Bioleg Canser a Therapiwteg a addysgir, rwy'n cyfrannu at ddylunio/rheoli, cyflawni, ac asesu ar gyfer y moleciwlau canlynol: PHT801 (Bioleg Moleciwlaidd Cellog a Moleciwlaidd Canser), PHT802 (Oncoleg Drosi a Therapiwteg), PHT803 (Sgiliau Ymchwil Academaidd), PHT804 (Methodoleg Ymchwil), PHT805 (Prosiect Ymchwil) a PHT806 (dadansoddi data a biowybodeg).
Fi yw arweinydd modiwl PHT806 (Biowybodeg) ac rwyf hefyd yn arwain sawl uned o fewn PHT801 a PHT802
Rwy'n oruchwyliwr ar gyfer prosiectau ymchwil canser ar PHT805 (ymchwil yn y labordy a fel arall).

Addysgu allanol:

Prifysgol Brighton PYM14 modiwl pwnc arbennig canser: darlithydd ar fiowybodeg i fiolegwyr canser

Ces i BSc (Anrh) ym 1985 mewn Gwyddorau Ffisiolegol o Brifysgol Newcastle-Upon-Tyne. Yna ymgymerais ag ysgoloriaeth ymchwil PhD a ariannwyd gan y Cyngor Ymchwil Feddygol yng Ngholeg Meddygaeth Prifysgol Cymru yn labordy canser y fron fu’n rhan o Sefydliad Tenovus bryd hynny (dyfarnwyd y PhD ym 1991) yn archwilio effaith gwrth-estrogenau ar y fron arferol.

Yn dilyn fy PhD, daliais 3 swydd ymchwil canser y fron ôl-ddoethurol yn olynol yn Sefydliad Tenovus rhwng 1991-2000 (gan gynnwys un gyda Llawfeddygaeth Adrannol, Coleg Meddygaeth Prifysgol Cymru yn archwilio DCIS clinigol cyn-neoplastig), gan ddod yn Uwch Ymchwilydd Ôl-ddoethurol ym 1995.

Rhwng 2000 ac Ebrill 2007, ymgymerais â swydd Uwch Gydymaith Ymchwil a Chydlynydd Ymchwil ar gyfer grŵp Canolfan Tenovus ar gyfer Ymchwil Canser yn Ysgol Fferylliaeth a Gwyddorau Fferyllol Caerdydd, gan ganolbwyntio ar ymwrthedd a dilyniant mewn canser y fron. Ochr yn ochr â chyfrannu at reoli grŵp Tenovus, fy rôl oedd goruchwylio ei Dîm Imiwnocytocemeg Clinigol, gan ymestyn i ddadansoddi elfennau signalu gan ddefnyddio gwrthgyrff sy'n benodol i actifadu mewn sawl treial canser y fron Cam II. Roedd fy nhîm yn chwaraewr allweddol yn astudiaethau biofarcwyr clinigol Cam II a ddarparodd dystiolaeth sylfaenol ar gyfer cymeradwyaeth FDA/UE o Faslodex ar gyfer canser datblygedig y fron. Fe wnes i hefyd gydlynu gwaith Darganfod Genynnau yn y grŵp, gan gymhwyso micro-araeau a biowybodeg i ddatgelu signalau newydd mewn modelau canser y fron sydd ag ymwrthedd. Cefais fy ariannu tan fis Medi 2010 fel Prif Ymchwilydd ar grant rhaglen Elusen Tenovus yn ymchwilio i sut i wella ymateb i driniaeth mewn celloedd canser y fron ER+.

Yna dyfarnwyd Cymrodoriaeth Wyddonol 5 mlynedd o fri gyda Breast Cancer Now (Ymgyrch Canser y Fron bryd hynny) (2010-2015) i mi yn Ysgol Fferylliaeth a Gwyddorau Fferyllol Caerdydd, i ddatblygu modelau celloedd newydd ac i ddefnyddio’r rhain i archwilio effaith cysylltiad â gwrth-hormonau ar y ffenoteip gwrthsefyll caffaeledig mewn clefyd ER+. Wedi hynny yn 2015, cefais fy mhenodi’n Uwch Ddarlithydd yn yr Ysgol, lle mae fy niddordebau ymchwil ar hyn o bryd yn canolbwyntio ar golli derbynyddion estrogen a achosir gan hormonau ac ennill signalau andwyol amgen mewn modelau canser y fron, astudiaethau biofarciwr mewn canser y fron clinigol, ac yn ddiweddaraf, archwilio sensitifrwydd therapi ffotodeinamig o wahanol isdeipiau canser y fron.

Mae rhan sylweddol o fy rôl fel Uwch Ddarlithydd hefyd yn cynnwys cyfrannu at ddylunio/rheoli, cyflwyno addysgu, ac asesu ar gyfer rhaglen Meistr a addysgir hynod lwyddiannus yr Ysgol mewn Bioleg a Therapiwteg Canser, yn ogystal â chyfrannu at addysgu ar gwrs MPharm yr Ysgol yn y meysydd trin canser ac endocrinoleg atgenhedlu.

Anrhydeddau a dyfarniadau

Gold medal, 9th World Congress on Advances in Oncology/7th International Symposium on Molecular Medicine, for my group's microarray and bioinformatic research in resistant breast cancer cells (2002)

Aelodaethau proffesiynol

Aelod etholedig o Grŵp y Fron Prydain.
Aelod gwadd o Fwrdd Golygyddol ar gyfer Journal of Hormone Molecular Biology and Clinical Investigation 2010
Aelod gwadd o Fwrdd Golygyddol BMC Cancer Journal 2010
Aelod gwadd o'r Bwrdd Golygyddol ar gyfer Endocrinology Journal 2009-2012
Cyd-olygydd ar gyfer Gweithdai Tenovus/AstraZeneca 1af-3ydd (2005, 2006, 2008).
Rwy’n gwasanaethu fel Gohebydd gwahoddedig ar gyfer Ymchwil Canser y Fron Ar-lein 2003-2006.
Dyfarnwr rheolaidd ac adolygydd cymheiriaid ar gyfer cyfnodolion gwyddonol gan gynnwys JNCI, cyfnodolion Nature, Breast Cancer Research, Endocrinology, ac ar gyfer cyrff cyllido gan gynnwys CR-UK (TRICC), MRC, Ymchwil Canser Swydd Efrog; Cronfa Ganser Iwerddon; Ymgyrch Canser y Fron; Ysbyty Weston Park Sheffield

Safleoedd academaidd blaenorol

2015- present: Senior Lecturer, Cardiff School of Pharmacy & Pharmaceutical Sciences, Cardiff University
2010-2015: Breast Cancer Now Scientific Fellow, Breast Cancer Molecular Pharmacology Group, Cardiff School of Pharmacy & Pharmaceutical Sciences, Cardiff University
2000-2010: Senior Research Associate, Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff University
1993-1999: Postdoctoral Researcher, Tenovus Centre for Cancer Research, University of Wales College of Medicine
1991-1993: Junior Postdoctoral Research Fellow (interdisciplinary award between Tenovus Cancer Research Centre & Dept. Surgery), University of Wales College of Medicine
1988-1991: Research Technician, Tenovus Cancer Research Centre, University of Wales College of Medicine

Pwyllgorau ac adolygu

Cynrychiolydd ôl-ddoethurol ar Bwyllgor Ymchwil yr Ysgol Fferylliaeth a Gwyddorau Fferyllol ers 2010
Aelod Sylfaenol o Goleg Ymchwilwyr Ôl-ddoethurol yr Ysgol Fferylliaeth a Gwyddorau Fferyllol
Aelod gweithgar o Grŵp y Fron Sefydliad Canser Cymru, grŵp CRUK-ECMC Caerdydd, a grŵp Canser Sartre Caerdydd/Bryste
Aelod presennol (a chydymgeisydd a enwir) o grŵp astudio treial canser y fron ABC (TRICC tamoxifen relapse)
Aelod etholedig o Grŵp y Fron Prydain, ac aelod o Bwyllgor y Rhaglen Wyddonol a etholwyd yn ddiweddar ers 2010
Aelod gwadd o Bwyllgor Mynediad Banc Meinweoedd ar gyfer Elusen Ymgyrch Canser y Fron ers 2010
Aelod o Fwrdd Gwyddonol Cynhadledd Ymchwil Canser y Fron Prydain, Nottingham UK, ers mis Ionawr 2010
Aelod o Bwyllgor Trefnu Cyfarfodydd Gwyddonol Ymgyrch Canser y Fron ers 2006. Hefyd Aelod o'r Pwyllgor ar gyfer (a chyd-awdur y ddogfen ganlyniadol ar ei gyfer) Dadansoddiad Bwlch Cenedlaethol mewn canser y fron a ysgogwyd gan Ymgyrch Canser y Fron. Amlygodd hyn feysydd o flaenoriaeth ar gyfer ymchwil wyddonol canser y fron yn y DU. Thompson A, Brennan K, Cox A, Gee J, Harcourt D, Harris A, Harvie M, Holen I, Howell A, Nicholson R, Steel M, Streuli C. Gwerthusiad o'r cyfyngiadau gwybodaeth cyfredol mewn ymchwil canser y fron: dadansoddiad bwlch. Breast Cancer Res. 2008;10(2):R26.
Trefnu Gweithdai Tenovus/AstraZeneca ar Ganser (1af, 2005; 2il, 2006; 3ydd, Gweithdy "Therapeutic Resistance to anti-hormonal drugs in breast cancer: new molecular aspects and targets Mai 2008, Caerdydd). Cyhoeddwyd trafodion o'r Gweithdai hyn fel atchwanegiadau yn y cyfnodolyn Endocrine Related Cancer ac yng nghyhoeddiad llyfr Springer (2009) “Gwrthiant therapiwtig i gyffuriau gwrth-hormonaidd yng nghanser y fron: agweddau moleciwlaidd newydd a'u potensial fel targedau”.
Aelod blaenorol o'r Bwrdd Cynghori Gwyddonol ar gyfer Ymgyrch Canser y Fron (2004-2007)
Aelod blaenorol o Oncopool (“Cyfuno Data Ewropeaidd i Gysoni Ymchwil Drosiadol mewn Canser y Fron”) Grŵp Astudio Canser y Fron Ewropeaidd (2002-2004)
Cydlynydd Imiwnocytocemeg NEQAS ar gyfer Canolfan Ymchwil Canser Tenovus (2001-2008)
Gwasanaethodd yn flaenorol ar Baneli Cynghori ac Adolygu Patholeg AstraZeneca a Thargedau Moleciwlaidd Canser y Fron (2001; Ebrill 2008)

Mae gen i ddiddordeb mewn goruchwylio myfyrwyr PhD ym meysydd:

Ymchwil Canser y Fron, yn benodol:

Deall mecanweithiau signalau ymateb triniaeth canser a methiant
Astudiaethau trosi - darganfod targedau/biofarcwyr newydd gan ddefnyddio modelau celloedd ac archwilio'r rhain mewn samplau canser y fron clinigol (rwyf hefyd wedi cyd-oruchwylio prosiectau MD yn y meysydd hyn o'r blaen)

Goruchwyliaeth bresennol ym maes ymchwil canser y fron:

Ar hyn o bryd rwy'n goruchwylio'r myfyriwr PhD Robin Aske ar gyfer ei brosiect "Design, Synthesis And Biological Evaluation Of Polymer Therapeutics For Photodynamic Treatment In Different Breast Cancer Phenotypes".
Rwyf hefyd yn cyfrannu at gyd-oruchwylio nifer o brosiectau PhD pellach gan gynnwys Zoe Hudson (MEDIC) ar "Investigation Of Biomarker Determinants Of Treatment Efficacy Of Fulvestrant And The Ret Inhibitor Vandetanib In Oestrogen Receptor Positive Breast Cancer" ac Ahmed Eissa ar "4th generation aromatase inhibitors for the treatment of breast cancer: design, synthesis, biochemical and molecular biology studies".
Rydw i hefyd yn cynnal prosiectau ymchwil 3 mis sy'n canolbwyntio ar ganser y fron ar gyfer y rhaglen MSc Bioleg Canser a Therapiwtigau a Addysgir gan Radd Meistr yn yr Ysgol.

Goruchwylio ar hyn o bryd

Robin Aske

Myfyriwr ymchwil

Prosiectau yn y gorffennol

Ers 2014:

Prif Oruchwyliwr ar gyfer:

Benyamin Ertefai "Resistance mechanisms during endocrine treatment in breast cancer" (dyfarnwyd 2016)
Hayley Francies "Characterising response and resistance mechanisms to Faslodex in breast cancer" (dyfarnwyd 2014)
Cyd-oruchwyliaeth i sawl myfyriwr gan gynnwys:
Silvia Ziliotto "Understanding how targeting zinc transporters prevents the development of aggressive cancer" (dyfarnwyd 2019)
Jessica Davis (MEDIC) "Identification of novel anti-hormone induced pro-survival genes in oestrogen receptor-positive breast cancer cells" (dyfarnwyd 2017)
Rebecca Bellerby: "The exploration of CD44 as a mediator of a drug resistant phenotype in ER+ breast cancer" (dyfarnwyd 2015)

Goruchwyliaeth gyfredol

Robin Aske

Myfyriwr ymchwil

Myfyrwyr o’r Ysgol Fferylliaeth yn camu’n ôl mewn amser i ddathlu canmlwyddiant

18 November 2019

Cardiff University STEM Day students visit to Pharmacy

26 June 2016

External profiles

ORCID

Dr Julia Gee

Trosolwyg

Cyhoeddiad

2024

2023

2022

2020

2019

2018

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1988

Articles

Book sections

Conferences

Ymchwil

Meysydd ymchwil:

Arbenigedd ymchwil:

Diddordebau ymchwil cyfredol:

Cydweithwyr ymchwil cenedlaethol a rhyngwladol cyfredol:

Cyrff cyllido a diwydiant sydd wedi cefnogi ein hymchwil:

Addysgu

MPharm:

MSc Bioleg Canser a Therapiwteg:

Addysgu allanol:

Bywgraffiad

Anrhydeddau a dyfarniadau

Aelodaethau proffesiynol

Safleoedd academaidd blaenorol

Pwyllgorau ac adolygu

Meysydd goruchwyliaeth

Goruchwyliaeth gyfredol

Robin Aske

Newyddion cysylltiedig

Myfyrwyr o’r Ysgol Fferylliaeth yn camu’n ôl mewn amser i ddathlu canmlwyddiant

Cardiff University STEM Day students visit to Pharmacy

External profiles